The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Cool and calm

Journal: Non Nocere. New Therapeutic Journal. 2024;(8): 82‑93

Read: 303 times

To cite this article:

Cool and calm. Non Nocere. New Therapeutic Journal. 2024;(8):82‑93. (In Russ.)

References:

  1. Harlow SD, Gass M, Hall JE, et al. STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012 Apr;19(4):387-395.  https://doi.org/10.1097/gme.0b013e31824d8f40
  2. Rossmanith WG, Ruebberdt W. What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol. 2009 May;25(5):303-314.  https://doi.org/10.1080/09513590802632514
  3. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013 Aug;34(3):211-227.  https://doi.org/10.1016/j.yfrne.2013.07.003
  4. Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD. A Neural Circuit Underlying the Generation of Hot Flushes. Cell Rep. 2018 Jul 10;24(2):271-277.  https://doi.org/10.1016/j.celrep.2018.06.037
  5. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol. 2003 Feb;101(2):264-272.  https://doi.org/10.1016/s0029–7844(02)02593–0
  6. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med. 2008 Sep;23(9):1507-1513. https://doi.org/10.1007/s11606-008-0655-4
  7. Whiteley J, DiBonaventura Md, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health (Larchmt). 2013 Nov;22(11):983-990.  https://doi.org/10.1089/jwh.2012.3719
  8. Orenstein BW, Smythe K. Menopause Symptoms That May Surprise You. Everyday health [Electronic resource]. 1 October 2023. Accessed July 9, 2024. https://earthsecret.com/blogs/journal/9-unusual-menopause-symptoms-that-might-surprise-you
  9. Kravitz HM, Zhao X, Bromberger JT, Gold EB, Hall MH, Matthews KA, Sowers MR. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep. 2008 Jul;31(7):979-990.  https://doi.org/10/5666|sleep/31.7.979
  10. Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2003 Jan;60(1):29-36.  https://doi.org/10.1001/archpsyc.60.1.29
  11. Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry. 2003 Aug;160(8):1519-1522. https://doi.org/10.1176/appi.ajp.160.8.1519
  12. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15(10):797-817.  https://doi.org/10.2165/00023210-200115100-00005
  13. Ministry of Health of the Russian Federation. Clinical Recommendations “Menopause and menopausal state in a woman” [Electronic resource]. ID: 117. Year of approval: 2021. Date of circulation: 09.07.2024. https://cr.minzdrav.gov.ru/schema/117_2?ysclid=ly7i98csk995312415
  14. Sikon A, Thacker HL. Treatment options for menopausal hot flashes. Cleve Clin J Med. 2004 Jul;71(7):578-582.  https://doi.org/10.3949/ccjm.71.7.578
  15. McGarry K, Geary M, Gopinath V. Beyond Estrogen: Treatment Options for Hot Flashes. Clin Ther. 2018 Oct;40(10):1778-1786. https://doi.org/10.1016/j.clinthera.2018.08.010
  16. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. [No authors listed] Menopause. 2015 Nov;22(11):1155-1174. https://doi.org/10.1097/GME.0000000000000546
  17. Fenlon D, Morgan A, Khambaita P, et al. Management of hot flushes in UK breast cancer patients: clinician and patient perspectives. J Psychosom Obstet Gynaecol. 2017 Dec;38(4):276-283.  https://doi.org/10.1080/0167482X.2017.1350163
  18. Mosolov S.N., Kostyukova E.G., Gorodnichev A.V., Timofeev I.V., Ladyzhensky M.Y., Serditov O.V. Clinical efficacy and tolerability of venlafaxine (Velaxin) in the treatment of moderate and severe depression. Modern therapy of psychiatric disorders. 2007;(3)58-63. 
  19. Becker R.A., Bykov Y.V. Velaxin® in capsules: introduction of a new prolonged form and review of the latest efficacy and safety data. Psychiatry and Psychopharmacotherapy. 2017;19(6):33-41. 
  20. Gillett G, Tomlinson A, Efthimiou O, Cipriani A. Predicting treatment effects in unipolar depression: A meta-review. Pharmacol Ther. 2020 Aug;212:107557. https://doi.org/10.1016/j.pharmthera.2020.107557
  21. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000 Dec 16;356(9247):2059-2063. https://doi.org/10.1016/S0140-6736(00)03403-6
  22. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011 Oct 10;29(29):3862-3868. https://doi.org/10.1200/JCO.2010.33.1298
  23. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist. 2007 Jan;12(1):124-135.  https://doi.org/10.1634/theoncologist.12-1-124
  24. Li T, Yang J, Lv Y, et al. Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer. Breast Cancer Res Treat. 2019 Feb;173(3):511-520.  https://doi.org/10.1007/s10549–018–5029-y
  25. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
  26. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 1995 Oct;56(10):450-458. 
  27. Krasnov V.N., Kryukov V.V. Velaxin (venlafaxine) in modern therapy of depression: results of the first Russian multicenter study of efficacy and safety. Psychiatry and Psychopharmacotherapy. 2007;4(9):29-32. 
  28. Cervera-Enguix S, Soutullo CA, Landecho I, Murillo-Jelsbak R. Quality of Life in 833 outpatients with major depression treated with open-label venlafaxine extended release: An observational 24-week study. Int J Psychiatry Clin Pract. 2003;7(3):193-197.  https://doi.org/10.1080/13651500310001446
  29. Avedisova A.S. Remission in antidepressant therapy: a sign of stabilization of the state or reduction of the process activity. Psychiatry and psychopharmacotherapy. 2008;2(10):33-37. 
  30. State Register of Medicines. Instruction for medical use of the medicinal product Velaxin [Electronic resource]. ND number: LP-NO (002093)-(RG-RU)-131223. Date of circulation: 09.07.2024. https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=88cd5f59-e940-4f0e-9bc1-56a36c8dc95f

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.